Loading clinical trials...
Loading clinical trials...
A 24 Week, Randomised, Assessor Blinded, Active-controlled, Parallel Group, Phase 3, 2 Arm Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
Conditions
Interventions
Delgocitinib
Toctino
Locations
102
Austria
LEO Pharma Investigational Site
Graz, Austria
LEO Pharma Investigational Site
Linz, Austria
LEO Pharma Investigational Site
Linz, Austria
LEO Pharma Investigational Site
Calgary, Canada
LEO Pharma Investigational Site
Calgary, Canada
LEO Pharma Investigational Site
Edmonton, Canada
Start Date
June 15, 2022
Primary Completion Date
November 8, 2023
Completion Date
December 5, 2023
Last Updated
May 9, 2025
NCT04872101
NCT05545215
NCT01482663
Lead Sponsor
LEO Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions